These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 26660535)

  • 1. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
    Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
    Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
    Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2019; 10():1350. PubMed ID: 31263464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.
    Chauvet S; Roumenina LT; Aucouturier P; Marinozzi MC; Dragon-Durey MA; Karras A; Delmas Y; Le Quintrec M; Guerrot D; Jourde-Chiche N; Ribes D; Ronco P; Bridoux F; Fremeaux-Bacchi V
    Front Immunol; 2018; 9():2260. PubMed ID: 30333829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains.
    Gilmore AC; Zhang Y; Cook HT; Lavin DP; Katti S; Wang Y; Johnson KK; Kim S; Pickering MC
    Kidney Int; 2021 Feb; 99(2):396-404. PubMed ID: 33129896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
    Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface.
    Pisarenka S; Meyer NC; Xiao X; Goodfellow R; Nester CM; Zhang Y; Smith RJH
    Front Immunol; 2022; 13():1073802. PubMed ID: 36846022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of C3 nephritic factor on the complement system--with special reference to stabilizing effect on C3 convertase (C3bBb) activity (author's transl)].
    Nakanishi I
    Nihon Jinzo Gakkai Shi; 1981 Jun; 23(6):719-32. PubMed ID: 6914399
    [No Abstract]   [Full Text] [Related]  

  • 15. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
    Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
    Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
    Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.
    Zhao F; Afonso S; Lindner S; Hartmann A; Löschmann I; Nilsson B; Ekdahl KN; Weber LT; Habbig S; Schalk G; Kirschfink M; Zipfel PF; Skerka C
    Front Immunol; 2019; 10():1030. PubMed ID: 31214159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
    Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
    Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causes of alternative pathway dysregulation in dense deposit disease.
    Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.